Գլխավոր Թոփ լուրեր Լրահոս Վիդեո Թրենդ

IDBank to Provide Scholarships Worth 35 Million Drams to 103 Artsakh Students at YSUUnibank joins the Partnership for Carbon Accounting Financials (PCAF)Safe environment – Equal opportunitiesAraratBank Receives STP Excellence Award from Commerzbank AGWorld Autism Awareness Day reminds us: culture is how we learn to see and embrace one anotherIDBank Receives Commerzbank’s STP Excellence Award 2025IDBank Presented a Special Offer at TOON EXPO 2026FINTECH360 International Conference to Bring Together 500 Participants in YerevanUcom Supports the DemArDem 2026 Regional Youth Forum Prominent Armenian Statesman Levon Sahakyan Passes Away at 89Ucom’s Unity Packages with the Best Fixed Network in Armenia Get 1% idcoin at TOON EXPO with Idram&IDBankUSD 60 Million: Ameriabank Joins Financing of Firebird’s AI Data Center Construction in ArmeniaStatement by Archbishop Bagrat Galstanyan Financial Literacy Course at YSU: Idram and IDBankAmeriabank named the Best Bank in Armenia for 2026 by Global Finance magazine IDBank warns about scams disguised as remote workAraratBank Donates Proceeds from "Armenian Legends and Poems" to the City of Smile Foundation The Power of One Dram Joins the Final Phase of the Symphonic Forest ProjectIdram&IDBank’s Special Offer at Dalma Garden MallUcom’s Management Team Marks International Client’s Day with Subscribers IDBank and Idram Continue Cooperation with the “ZARK” Educational FoundationIDBank issued the 2nd and 3rd tranches of bonds of 2026Ucom Issues Warning on New Wave of Phone Scams IDBank Launches Special Campaign for SWIFT TransfersConverse Bank shares its capital market expertise at the IV Conference Capital Markets ArmeniaUcom’s Level Up+ Packages with the Fastest Mobile Internet in Armenia The Badalyan Brothers Group of Companies Paid about 33.2 Billion AMD in Taxes and Duties to the State in 2025IDBank Announces the Launch of the IDDistributor Financial ToolSafe Workplace as a Guarantee of DevelopmentSpring Promotion at Megamall from Idram&IDBank“We want to buy your item, please provide your card details.” IDBank warns about fraud on classified platforms Ucom Fellowship 2025 Concludes as Top Eco-Startups Secure FundingIDBank Goes International: Mher Abrahamyan's Interview with the Los Angeles TimesAraratBank Earns RIA Money Transfer’s Partner of the Year in Armenia for the Seventh Consecutive YearUcom Supports the “DemArDem 2026” Regional Youth Forum ZCMC еstablishes Sustainability, ESG and Risk Committee Parallels Between the “Real Armenia Ideology” and Soviet and Turkish Approaches to the DiasporaNew Offer - Up to AMD 5 Million - Consolidate your Loans and Switch to AraratBankNew Promotion at Yerevan Mall Ahead of March 8: Idram&IDBankUBPay and MoneyTO Launch Money Transfers from Armenia to the UK In Celebration of the Spring Holidays Ucom Offers Unity Packages on Special Terms Ameriabank Becomes the First Armenian Company in the List of the 100 Largest Companies on the London Stock Exchange as a Member of Lion Finance GroupIDBank Expands Travel Benefits of Premium CardsFree Calls and SMS Messages from Ucom for Subscribers in the Middle EastLove Is… Card by Unibank – An Iconic Design and a Romantic Trip for Two to Paris Customer Appreciation Day at IDBank’s Echmiadzin BranchUcom Fellowship Incubation Program Participants Visit Ucom Individuals and businesses, near and far, all welcomeTrust and reach across the globe
Lifestyle

Experimental drug returns sight to former rugby player

Gene therapy returned sight for Rory Dewar, a former rugby player who lost his eyesight at the age of 22 due to a rare disorder, The Daily Mail reported.

Rory was diagnosed with Leber's hereditary optical neuropathy (LHON), in which healthy cells in the retina die due to a gene mutation, leading to the death of the optic nerve. One out of 30,000 people is affected by this disease, and it is usually either young people between the ages of 15 and 25, or menopausal women. Most patients do not know anything about the disease until their vision begins to deteriorate sharply. There is no cure and volunteers in the Colorado trial had a lab-engineered virus injected into their eyes.

The first results in Rory appeared within 24 hours after the injection. Rory says that he will always be grateful for his fate in participating in these clinical studies that have changed his life for the better.

GenSight Biologics representatives are now negotiating with the U.S. Food and Drug Administration and the European medical agency to get approval for their new medicine called Lumevoq.

Rory hopes that this medicine will be approved and that it will help other people with a serious, yet formally incurable disease.